HUBBARD, Ohio, Feb. 9, 2012 /PRNewswire/ -- NanoLogix (PINK
SHEETS: NNLX), an innovator in rapid diagnostics, today released a
comprehensive operations summary that revealed an exponential drop
in detection and diagnostic times for active-threat bacteria and
amoeba. This development is projected to provide reliable
detection, ease of use, and the ability to identify live
active-threat bacteria and differentiate from non-threat bacteria,
faster and at lower cost than other technologies.
In recent third-party tests, two of NanoLogix's products, the
BioNanoPore (BNP) and BioNanoFilter (BNF), provided diagnostic
results 4 to 20 times faster than standard tests. Group B
Streptococcus, a threat during pregnancy, took an hour or less
rather than the standard 48-72 hours. Tuberculosis detection was
reduced from weeks to 4 days.
These details are included in today's comprehensive summary of
NanoLogix business operations, which covers technology
advances, partnership collaborations, preparations for FDA
approvals, media coverage, financial information and the company's
new R&D laboratory.
To view the NanoLogix Company Summary, please visit:
http://nanologix.com/news/2011_company_update.html
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing.
Patents pending and granted to NanoLogix can be used in the
areas of clinical diagnostics, applied microbiology, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and
antibiotic sensitivity.
For more information visit www.nanologix.com.
Media Contact:
Lisa Ann Pinkerton
650-288-1824
Lisaann@technicacommunications.com
Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
SOURCE NanoLogix, Inc.